Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 291 (1), 190-213

Pathogenic B-cell Receptor Signaling in Lymphoid Malignancies: New Insights to Improve Treatment


Pathogenic B-cell Receptor Signaling in Lymphoid Malignancies: New Insights to Improve Treatment

Ryan M Young et al. Immunol Rev.


Signals emanating from the B-cell receptor (BCR) promote proliferation and survival in diverse forms of B-cell lymphoma. Precision medicine strategies targeting the BCR pathway have been generally effective in treating lymphoma, but often fail to produce durable responses in diffuse large B-cell lymphoma (DLBCL), a common and aggressive cancer. New insights into DLBCL biology garnered from genomic analyses and functional proteogenomic studies have identified novel modes of BCR signaling in this disease. Herein, we describe the distinct roles of antigen-dependent and antigen-independent BCR signaling in different subtypes of DLBCL. We highlight mechanisms by which the BCR cooperates with TLR9 and mutant isoforms of MYD88 to drive sustained NF-κB activity in the activated B-cell-like (ABC) subtype of DLBCL. Finally, we discuss progress in detecting and targeting oncogenic BCR signaling to improve the survival of patients with lymphoma.

Keywords: B-cell receptor; cancer; lymphoma; signal transduction.

Conflict of interest statement

Conflict of Interest

The authors declare no conflicts of interest.

Similar articles

  • A multiprotein supercomplex controlling oncogenic signalling in lymphoma.
    Phelan JD, Young RM, Webster DE, Roulland S, Wright GW, Kasbekar M, Shaffer AL 3rd, Ceribelli M, Wang JQ, Schmitz R, Nakagawa M, Bachy E, Huang DW, Ji Y, Chen L, Yang Y, Zhao H, Yu X, Xu W, Palisoc MM, Valadez RR, Davies-Hill T, Wilson WH, Chan WC, Jaffe ES, Gascoyne RD, Campo E, Rosenwald A, Ott G, Delabie J, Rimsza LM, Rodriguez FJ, Estephan F, Holdhoff M, Kruhlak MJ, Hewitt SM, Thomas CJ, Pittaluga S, Oellerich T, Staudt LM. Phelan JD, et al. Nature. 2018 Aug;560(7718):387-391. doi: 10.1038/s41586-018-0290-0. Epub 2018 Jun 20. Nature. 2018. PMID: 29925955 Free PMC article.
  • B-cell receptor signaling as a driver of lymphoma development and evolution.
    Niemann CU, Wiestner A. Niemann CU, et al. Semin Cancer Biol. 2013 Dec;23(6):410-21. doi: 10.1016/j.semcancer.2013.09.001. Epub 2013 Sep 20. Semin Cancer Biol. 2013. PMID: 24060900 Free PMC article. Review.
  • Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma.
    Davis RE, Ngo VN, Lenz G, Tolar P, Young RM, Romesser PB, Kohlhammer H, Lamy L, Zhao H, Yang Y, Xu W, Shaffer AL, Wright G, Xiao W, Powell J, Jiang JK, Thomas CJ, Rosenwald A, Ott G, Muller-Hermelink HK, Gascoyne RD, Connors JM, Johnson NA, Rimsza LM, Campo E, Jaffe ES, Wilson WH, Delabie J, Smeland EB, Fisher RI, Braziel RM, Tubbs RR, Cook JR, Weisenburger DD, Chan WC, Pierce SK, Staudt LM. Davis RE, et al. Nature. 2010 Jan 7;463(7277):88-92. doi: 10.1038/nature08638. Nature. 2010. PMID: 20054396 Free PMC article.
  • Targeting the B-cell receptor pathway in diffuse large B-cell lymphoma.
    Dunleavy K, Erdmann T, Lenz G. Dunleavy K, et al. Cancer Treat Rev. 2018 Apr;65:41-46. doi: 10.1016/j.ctrv.2018.01.002. Epub 2018 Feb 1. Cancer Treat Rev. 2018. PMID: 29549872 Review.
  • Tonic B-cell receptor signaling in diffuse large B-cell lymphoma.
    Havranek O, Xu J, Köhrer S, Wang Z, Becker L, Comer JM, Henderson J, Ma W, Man Chun Ma J, Westin JR, Ghosh D, Shinners N, Sun L, Yi AF, Karri AR, Burger JA, Zal T, Davis RE. Havranek O, et al. Blood. 2017 Aug 24;130(8):995-1006. doi: 10.1182/blood-2016-10-747303. Epub 2017 Jun 23. Blood. 2017. PMID: 28646116 Free PMC article.
See all similar articles

Cited by 3 articles

Publication types

MeSH terms

LinkOut - more resources